![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
bluebird bio
Main focus: Gene therapies and gene editing for the treatment of genetic diseases
Company stage: Clinical
Diseases (gene editing): Haemophilia and other severe genetic diseases
Genome editing tool: megaTAL
Funding stage: Public
Location: Cambridge, MA, USA
Website: https://www.bluebirdbio.com/
Pipeline: https://www.bluebirdbio.com/our-science/pipeline
Gene editing partnerships: Novo Nordisk
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_bluebird_bio_d59b8c2765_50d3bf86ae.png)
bluebird bio develops novel gene and cancer therapies. The company is developing its proprietary megaTAL gene-editing technology, although it still has to disclose its first pre-clinical candidate derived from this. The company has a collaboration with Novo Nordisk to jointly develop next generation in vivo genome-editing treatments for genetic diseases, including haemophilia.